

# Steroid Sulfatase Inhibitors For Hormone Related Cancers

Tech ID: 32261 / UC Case 2018-622-0

## ABSTRACT

Researchers at the University of California, Davis have developed several steroid sulfatase inhibitors (STSi) that can be used as a potential treatment for hormone related cancers, specifically castration resistant prostate cancer (CRPC) and breast cancer.

#### **FULL DESCRIPTION**

Prostate cancer growth is often driven by androgens, which are male sex hormones such as testosterone. Currently, common treatment options for prostate cancer focus on lowering the levels of androgens in a man's body by surgical castration or by hormone therapy called androgen deprivation therapy (ADT). Despite advances in ADT that provide temporary relief from symptoms, patients often develop resistances to hormonal drugs and there is still no definitive cure for castration resistant prostate cancer (CRPC). High levels of cholesterol and its subsequent product dehydroepiandrosterone (DHEA) are observed in cell sublines that are resistant to ADT drugs. Emerging clinical evidence also shows DHEA concentration is highly elevated in advanced prostate cancer. DHEA synthesis is mediated by steroid sulfatase (STS), therefore inhibition of STS may be a viable strategy to treat resistant prostate cancer.

Researchers at the University of California, Davis have developed several steroid sulfatase inhibitors (STSi) that can be used as a potential treatment to prostate cancer, specifically CRPC. STSi can hinder the growth of cells that are resistant to ADT drugs such as enzalutamide and abiraterone, and thus potentially prolong the effectiveness of ADT. STSi can also potentially decrease the resistance of existing cells and re-sensitize them to ADT treatments. Results from *in vivo* testing has shown that STSi significantly inhibited VCaP tumor growth, which is a type of prostrate tumor particularly is resistant to ADT treatment. Moreover, in vitro testing has shown that STSi also inhibits breast cancer cell growth.

#### APPLICATIONS

- Acts as a potential tumor inhibitor for prostrate and breast cancer
- > Potentially prolongs ADT efficacy by hindering existing resistant cell lines and preventing
- the growth of more ADT resistant cells

#### **FEATURES/BENEFITS**

▶ Potentially increases ADT efficacy particularly for resistant prostate cancer

#### **PATENT STATUS**

Patent Pending

## CONTACT

Victor Haroldsen haroldsen@ucdavis.edu tel: 530-752-7717.



### **INVENTORS**

► Gao, Allen C.

#### OTHER INFORMATION

**KEYWORDS** Prostate cancer, Breast cancer, Oncology, DHEA, Dehydroepiandrosterone, ADT, Androgen deprivation therapy, Steroid sulfatase, STS, STSI

CATEGORIZED AS

Medical

Disease: Cancer

Disease: Women's
Health
Therapeutics

RELATED CASES
2018-622-0

- ▶ Novel Prostate Cancer Treatment
- AKR1C3 and Androgen Receptor-Inhibiting Compounds for Treatment of Advanced Cancers
- ▶ Inhibitors of Bromodomain and Extra-Terminal (BET) Family Proteins as Potential Treatments for Drug-Resistant Tumors

University of California, Davis	Tel:	$\odot$ 2021, The Regents of the University of California	
Technology Transfer Office	530.754.8649		<u>Terms of use</u>
1 Shields Avenue, Mrak Hall 4th Floor,	techtransfer@ucda	<u>vis.edu</u>	Privacy Notice
Davis,CA 95616	https://research.ucdavis.edu/technology-		
	<u>transfer/</u>		
	Fax:		
	530.754.7620		